Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/13/2019 06:40 PDT] ALBO Expected to Trade Up After Bullish Patterns Develop
• [06/04/2019 07:50 PDT] ALBO Expected to Trade Up After Bullish Patterns Develop
• [04/30/2019 12:43 PDT] Albireo Pharma, Inc. (NASDAQ:ALBO), Up By 100.00% ($31.88) From $31.880 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/30/2019 10:29 PDT] Albireo Pharma, Inc. (NASDAQ:ALBO), Up By 100.00% ($30.80) From $30.800 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/26/2019 07:39 PDT] ALBO Expected to Trade Up After Bullish Patterns Develop
• [04/25/2019 07:51 PDT] ALBO Expected to Trade Up After Bullish Patterns Develop